Merz Gets Untitled Letter for Inflated Marketing Claims

August 19, 2013
The FDA flagged Merz Pharmaceuticals for a web page and banners that the agency says ignore risk information and make overblown claims surrounding its anti-fungal treatment Naftin. One item scrutinized in an untitled letter to Merz is the claim that Naftin (naftifine hydrochloride) has a two-week treatment period unlike its competitors. The agency doesn’t know of any head-to-head studies that demonstrate Naftin is superior to other treatment options, the letter states.
Washington Drug Letter